Protocol: P07037 New Investigational Medication for Moderate to Severe Parkinson’s Disease

A 12-week, Double-blind, Placebo-controlled Efficacy and Safety Study of Preladenant  for Patients with Moderate to Severe Parkinson’s Disease.

Major Inclusion/Exclusion:

  • Ages 30 to 85
  • Must have diagnosis of Idiopathic Parkinson’s Disease.
  • Must currently be taking at least 1 year of ongoing therapy with Levodopa.
  • Must not have any other form of Parkinson’s or cognitive impairment.

Alpine Clinical Research Center
1000 Alpine Avenue, Suite 200
Boulder, CO 80304
Phone: 303-443-7229